MacroGenics (NASDAQ: MGNX) officer prepares stock sales under Rule 144

Rhea-AI Filing Summary

MACROGENICS INC (MGNX) has a notice of proposed share sales filed under Rule 144 on behalf of officer Jeffrey Peters. The filing lists multiple blocks of common stock acquired through “stock plan activity” on dates in 2025 and 2026 that may be sold through Merrill Lynch on NASDAQ after the Rule 144 conditions are met.

Key Figures

Stock plan activity block 1: 5,526 shares Stock plan activity block 2: 8,185 shares Stock plan activity block 3: 3,684 shares +4 more

7 metrics

Stock plan activity block 1 5,526 shares Common stock tied to stock plan activity dated 02/08/2025

Stock plan activity block 2 8,185 shares Common stock tied to stock plan activity dated 02/15/2025

Stock plan activity block 3 3,684 shares Common stock tied to stock plan activity dated 02/07/2026

Stock plan activity block 4 5,525 shares Common stock tied to stock plan activity dated 02/08/2026

Stock plan activity block 5 8,185 shares Common stock tied to stock plan activity dated 02/15/2026

Issuer phone number 3012515172 Contact telephone number for MACROGENICS INC as listed with the issuer address

Notice date 08/19/2026 Date appearing with the Form 144 notice and signature section

Key Terms

Rule 144, stock plan activity, securities to be sold

3 terms

Rule 144 regulatory

"See the definition of "person" in paragraph (a) of Rule 144."

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

stock plan activity financial

"Common | 02/08/2025 | Stock plan activity | Issuer"

securities to be sold financial

"144: Securities To Be Sold Common | 02/08/2025 | Stock plan activity"

FAQ

What does the Form 144 filing for MGNX by Jeffrey Peters disclose?

The Form 144 discloses that Jeffrey Peters, an officer of MACROGENICS INC (MGNX), intends to sell common shares under Rule 144, with the shares originating from company stock plan activity on several dates in 2025 and 2026.

Which MACROGENICS (MGNX) officer is associated with this Form 144?

The notice relates to Jeffrey Peters, identified as an officer of MACROGENICS INC. The filing states that the securities to be sold are for his account and provides details required for sales relying on Rule 144.

How are the MGNX shares in this Form 144 being transacted?

The Form 144 indicates the MGNX common shares may be sold through Merrill Lynch and are listed on NASDAQ. The shares come from prior stock plan activity with specific grant or activity dates in 2025 and 2026.

What are some share blocks listed in the MGNX Form 144 for Jeffrey Peters?

The filing lists several blocks of MGNX common stock tied to stock plan activity, including 5,526 shares dated 02/08/2025 and 8,185 shares dated 02/15/2025, plus additional blocks dated in 2026 from similar stock plan activity.

Does the Form 144 for MGNX show recent sales or only proposed sales?

The document functions as a notice of proposed sales under Rule 144, specifying common shares and dates of related stock plan activity. It is not a trade confirmation and does not itself demonstrate that the listed shares have already been sold.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/19/2026 - 05:20 PM Accepted by SEC EDGAR 08/19/2026 - 05:20 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001706903
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	MACROGENICS INC.
SEC File Number
Address of Issuer	9704 Medical Center Drive Rockville MARYLAND 20850
Phone	3012515172
Name of Person for Whose Account the Securities are To Be Sold	Jeffrey Peters
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Merrill Lynch 1800 K St NW Suite 800 Washington DC 20006	31105	129145	63700187	08/19/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	02/08/2025	Stock plan activity	Issuer			5526	02/08/2025	n/a
Common	02/15/2025	Stock plan activity	Issuer			8185	02/15/2025	n/a
Common	02/07/2026	Stock plan activity	Issuer			3684	02/07/2026	n/a
Common	02/08/2026	Stock plan activity	Issuer			5525	02/08/2026	n/a
Common	02/15/2026	Stock plan activity	Issuer			8185	02/15/2026	n/a

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks
Date of Notice	08/19/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	05/20/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	Jeffrey Peters
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)